Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease: Results of a Cohort Study.

Signorelli SS, Anzaldi M, Libra M, Navolanic PM, Malaponte G, Mangano K, Quattrocchi C, Di Marco R, Fiore V, Neri S.

Angiology. 2016 Oct;67(9):870-4. doi: 10.1177/0003319716633339. Epub 2016 Feb 17.

PMID:
26888895
2.

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS.

Adv Enzyme Regul. 2008;48:113-35. doi: 10.1016/j.advenzreg.2008.02.006. Epub 2008 Feb 21. No abstract available.

3.

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA.

Oncogene. 2008 Jul 3;27(29):4086-95. doi: 10.1038/onc.2008.49. Epub 2008 Mar 10.

4.

Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review).

Steelman LS, Navolanic PM, Franklin RA, Bonati A, Libra M, Stivala F, Martelli AM, McCubrey JA.

Mol Med Rep. 2008 Mar-Apr;1(2):139-60.

PMID:
21479390
5.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
6.

Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease.

Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino MC, Malaponte G.

J Clin Pathol. 2006 Feb;59(2):211-5.

7.

A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin.

Carbone A, Gloghini A, Libra M, Gasparotto D, Navolanic PM, Spina M, Tirelli U.

Mod Pathol. 2006 Feb;19(2):299-306.

8.

Analysis of hepatitis C virus infection among health-care workers: an observational study.

Proietti L, Malaponte G, Libra M, Navolanic PM, Bevelacqua Y, Travali S, Mazzarino MC.

Minerva Gastroenterol Dietol. 2005 Sep;51(3):255-9.

PMID:
16280967
9.

Pharmacological breast cancer therapy (review).

Navolanic PM, McCubrey JA.

Int J Oncol. 2005 Nov;27(5):1341-4. Review.

PMID:
16211230
10.

Analysis of BRAF mutation in primary and metastatic melanoma.

Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travali S, McCubrey JA.

Cell Cycle. 2005 Oct;4(10):1382-4. Epub 2005 Oct 13.

PMID:
16096377
11.

Hepatitis C virus (HCV) infection and lymphoproliferative disorders

Libra M, Gasparotto D, Gloghini A, Navolanic PM, De Re V, Carbone A.

Front Biosci. 2005 Sep 1;10:2460-71. Review.

PMID:
15970508
12.

Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease.

Signorelli SS, Malaponte G, Libra M, Di Pino L, Celotta G, Bevelacqua V, Petrina M, Nicotra GS, Indelicato M, Navolanic PM, Pennisi G, Mazzarino MC.

Vasc Med. 2005 Feb;10(1):1-6.

PMID:
15920993
13.

JH6 gene usage among HCV-associated MALT lymphomas harboring t(14;18) translocation.

Libra M, Gloghini A, Navolanic PM, Zignego AL, De Re V, Carbone A.

J Immunol. 2005 Apr 1;174(7):3839; author reply 3839. No abstract available.

14.

Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses.

Libra M, Gloghini A, De Re V, Rupolo M, Navolanic PM, Gasparotto D, Stivala F, Spina M, Boiocchi M, Carbone A.

Int J Oncol. 2005 Apr;26(4):945-50.

PMID:
15753988
15.

Second primary lymphoma or recurrence: a dilemma solved by VDJ rearrangement analysis.

Libra M, De Re V, Gloghini A, Navolanic PM, Carbone A, Boiocchi M.

Leuk Lymphoma. 2004 Aug;45(8):1539-43. Review.

PMID:
15370204
16.

Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection.

Libra M, De Re V, Gloghini A, Gasparotto D, Gragnani L, Navolanic PM, De Vita S, Mazzarino MC, Zignego AL, Carbone A, Boiocchi M.

Haematologica. 2004 Jul;89(7):873-4.

17.

Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy.

Libra M, Navolanic PM, Talamini R, Cecchin E, Sartor F, Tumolo S, Masier S, Travali S, Boiocchi M, Toffoli G.

BMC Cancer. 2004 Mar 25;4:11.

18.

Neosis and its potential role in cancer development and chemoresistance.

Navolanic PM, Akula SM, McCubrey JA.

Cancer Biol Ther. 2004 Feb;3(2):219-20. Epub 2004 Feb 1. No abstract available.

PMID:
14752274
19.

Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway.

Navolanic PM, Lee JT, McCubrey JA.

Cancer Biol Ther. 2003 Nov-Dec;2(6):677-8. No abstract available.

PMID:
14688475
20.

Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA.

Leukemia. 2003 Jul;17(7):1263-93. Review.

PMID:
12835716
21.

Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.

Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA, Mirza A, McMahon M, White MK, McCubrey JA.

Leukemia. 2003 Jun;17(6):1058-67.

PMID:
12764369
22.

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA.

Leukemia. 2003 Mar;17(3):590-603. Review.

PMID:
12646949
23.

Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.

Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA.

Leukemia. 2003 Mar;17(3):499-514. Review.

PMID:
12646938
24.

Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance.

Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV, McCubrey JA.

Clin Cancer Res. 2003 Mar;9(3):1161-70.

25.

Elucidation of signal transduction pathways by retroviral infection of cells with modified oncogenes.

Steelman LS, Blalock WL, Wang XY, Moye PW, Lee JT, Shelton JG, Navolanic PM, Davis JM, Knapp SL, Franklin RA, White MK, McCubrey JA.

Methods Mol Biol. 2003;218:221-52.

PMID:
12616724
26.

Elucidation of signal transduction pathways by transfection of cells with modified oncogenes.

Steelman LS, Blalock WL, Wang XY, Moye PW, Lee JT, Shelton JG, Navolanic PM, Davis JM, Knapp SL, Franklin RA, White MK, McCubrey JA.

Methods Mol Biol. 2003;218:203-20.

PMID:
12616723
27.

Fibroblastic, hematopoietic, and hormone responsive epithelial cell lines and culture conditions for elucidation of signal transduction and drug resistance pathways by gene transfer.

Steelman LS, Blalock WL, Wang XY, Moye PW, Lee JT, Shelton JG, Navolanic PM, Davis JM, Knapp SL, Franklin RA, White MK, McCubrey JA.

Methods Mol Biol. 2003;218:185-201. Review.

PMID:
12616722
28.

Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).

Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA.

Int J Oncol. 2003 Mar;22(3):469-80. Review.

PMID:
12579299
29.

EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review).

Navolanic PM, Steelman LS, McCubrey JA.

Int J Oncol. 2003 Feb;22(2):237-52. Review.

PMID:
12527919
30.

Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin.

Weinstein-Oppenheimer CR, Henríquez-Roldán CF, Davis JM, Navolanic PM, Saleh OA, Steelman LS, Franklin RA, Robinson PJ, McMahon M, McCubrey JA.

Clin Cancer Res. 2001 Sep;7(9):2898-907.

31.

Identification of isoforms of a mitotic motor in mammalian spermatogenesis.

Navolanic PM, Sperry AO.

Biol Reprod. 2000 May;62(5):1360-9.

PMID:
10775188

Supplemental Content

Loading ...
Support Center